303-81-1
Chemical Structure
Novobiocin
Synonym(s): Albamycin; Cathomycin
- CAS No.: 303-81-1
- Formula:C31H36N2O11
- Molecular Weight:612.62
IUPAC Name: (3R,4S,5R,6R)-5-hydroxy-6-((4-hydroxy-3-(4-hydroxy-3-(3-methylbut-2-en-1-yl)benzamido)-8-methyl-2-oxo-2H-chromen-7-yl)oxy)-3-methoxy-2,2-dimethyltetrahydro-2H-pyran-4-yl carbamate
InChIKey: YJQPYGGHQPGBLI-KGSXXDOSSA-N
SMILES: CC1=C(O2)C(C(O)=C(NC(C3=CC(C/C=C(C)/C)=C(O)C=C3)=O)C2=O)=CC=C1O[C@H]4[C@@H]([C@@H]([C@@H](OC)C(C)(C)O4)OC(N)=O)O
Biological Activity: Novobiocin (Albamycin; Cathomycin) is an orally active aminocoumarin antibiotic (Antibiotic) and Hsp90 inhibitor. Novobiocin binds to the C-terminal nucleotide-binding site of Hsp90 and inhibits the function of this chaperone; Novobiocin competitively blocks ATP binding to GyrB, targets ParE in N. gonorrhoeae, inhibits human POLθ ATPase and the POLθ helicase-like domain in a non-ATP-competitive manner, and inhibits the catalytic activity of human TOP2A and TOP2B. Novobiocin inhibits MMEJ, blocks the recruitment of POLθ to DNA damage sites, induces ssDNA gap formation and apoptosis (Apoptosis), and exhibits synthetic lethality in HR-deficient tumors. Novobiocin can be used for research on equine piroplasmosis, gonorrhea, HR-deficient tumors, anthrax, melioidosis, and acute promyelocytic leukemia[1][2][3][4][5][6][7].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Novobiocin | 97.88% | Novobiocin (Albamycin; Cathomycin) is an orally active aminocoumarin antibiotic (Antibiotic) and Hsp90 inhibitor. Novobiocin binds to the C-terminal nucleotide-binding site of Hsp90 and inhibits the function of this chaperone; Novobiocin competitively blocks ATP binding to GyrB, targets ParE in N. gonorrhoeae, inhibits human POLθ ATPase and the POLθ helicase-like domain in a non-ATP-competitive manner, and inhibits the catalytic activity of human TOP2A and TOP2B. Novobiocin inhibits MMEJ, blocks the recruitment of POLθ to DNA damage sites, induces ssDNA gap formation and apoptosis (Apoptosis), and exhibits synthetic lethality in HR-deficient tumors. Novobiocin can be used for research on equine piroplasmosis, gonorrhea, HR-deficient tumors, anthrax, melioidosis, and acute promyelocytic leukemia. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
-
Similarity Score 0.93
HY-13494711-Hydroxynovobiocin -
Similarity Score 0.92
HY-B0425ANovobiocin sodium -
Similarity Score 0.89
HY-141442Dihydronovobiocin -
Similarity Score 0.88
HY-137806Descarbamylnovobiocin -
Similarity Score 0.83
HY-162711Methylbiocin -
Similarity Score 0.76
HY-123515Clorobiocin -
Similarity Score 0.63
HY-141441Novobiocic acid -
Similarity Score 0.56
HY-108248KU-32 -
Similarity Score 0.52
HY-N1939RIcariside I (Standard) -
Explore the MedChemAI to find more analogs
References
- [1]. Suthar A, et al. Anti-piroplasmic activity of novobiocin as heat shock protein 90 inhibitor against in vitro cultured Theileria equi and Babesia caballi parasites. Ticks and tick-borne diseases. 2021 Jul;12(4):101696.
- [2]. Ishizaki Y, Hayashi C, Matoba K, Igarashi M. Novobiocin primarily targets ParE in Neisseria gonorrhoeae. J Antibiot (Tokyo). 2025 Feb;78(3):159-165. [Content Brief]
- [3]. Zhou J, et al. A first-in-class Polymerase Theta Inhibitor selectively targets Homologous-Recombination-Deficient Tumors. Nature cancer. 2021 Jun;2(6):598-610. [Content Brief]
- [4]. Syed A, et al. Novobiocin blocks nucleic acid binding to Polθ and inhibits stimulation of its ATPase activity. Nucleic Acids Res. 2023 Oct 13;51(18):9920-9937. [Content Brief]
- [5]. Klimko CP, et al. Efficacy of Treatment with the Antibiotic Novobiocin against Infection with Bacillus anthracis or Burkholderia pseudomallei. Antibiotics (Basel). 2022 Nov 23;11(12):1685. [Content Brief]
- [6]. Kubeš J, et al. Pharmacological correlates of topoisomerase II-directed protection against anthracycline-induced DNA damage and cardiotoxicity: a comparative evaluation of catalytic topoisomerase II inhibitors. Archives of toxicology. 2026 Oct 23. [Content Brief]
- [7]. Nitiss JL, et al. Targeting DNA topoisomerase II in cancer chemotherapy. Nature reviews. Cancer. 2009 May;9(5):338-50. [Content Brief]
